$199.85
00.00%
Pre-Market: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
CME Gr
CMENASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
CME Gr (NASDAQ:CME) Stock, Analyst Ratings, Price Targets, Forecasts
CME Group Inc has a consensus price target of $222.48 based on the ratings of 22 analysts. The high is $280 issued by Citigroup on April 28, 2022. The low is $187 issued by JP Morgan on June 21, 2024. The 3 most-recent analyst ratings were released by Barclays, Piper Sandler, and Keefe, Bruyette & Woods on July 10, 2024, July 9, 2024, and July 3, 2024, respectively. With an average price target of $223 between Barclays, Piper Sandler, and Keefe, Bruyette & Woods, there's an implied 11.58% upside for CME Group Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Piper Sandler
Keefe, Bruyette & Woods
JP Morgan
B of A Securities
1calculated from analyst ratings
Analyst Ratings for CME Gr
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | 4.08% | Barclays | Benjamin Budish | $228 → $208 | Maintains | Equal-Weight | Get Alert |
| 07/09/2024 | Buy Now | 17.59% | Piper Sandler | Richard Repetto | $250 → $235 | Maintains | Overweight | Get Alert |
| 07/03/2024 | Buy Now | 13.08% | Keefe, Bruyette & Woods | Kyle Voigt | $226 → $226 | Maintains | Market Perform | Get Alert |
| 06/21/2024 | Buy Now | -6.43% | JP Morgan | Kenneth Worthington | $206 → $187 | Downgrade | Neutral → Underweight | Get Alert |
| 04/25/2024 | Buy Now | 14.09% | Barclays | Benjamin Budish | $226 → $228 | Maintains | Equal-Weight | Get Alert |
| 04/25/2024 | Buy Now | 8.08% | B of A Securities | Craig Siegenthaler | $209 → $216 | Maintains | Neutral | Get Alert |
| 04/25/2024 | Buy Now | 3.08% | JP Morgan | Kenneth Worthington | $198 → $206 | Maintains | Neutral | Get Alert |
| 04/25/2024 | Buy Now | 13.08% | Keefe, Bruyette & Woods | Kyle Voigt | $222 → $226 | Maintains | Market Perform | Get Alert |
| 04/25/2024 | Buy Now | -6.43% | Rosenblatt | Andrew Bond | $185 → $187 | Reiterates | Sell → Sell | Get Alert |
| 04/09/2024 | Buy Now | 12.58% | Morgan Stanley | Mike Cyprys | $222 → $225 | Maintains | Equal-Weight | Get Alert |
| 04/08/2024 | Buy Now | 13.08% | Barclays | Benjamin Budish | $225 → $226 | Maintains | Equal-Weight | Get Alert |
| 04/05/2024 | Buy Now | 5.08% | Deutsche Bank | Brian Bedell | $235 → $210 | Downgrade | Buy → Hold | Get Alert |
| 04/03/2024 | Buy Now | 14.59% | Keefe, Bruyette & Woods | Kyle Voigt | → $229 | Maintains | Market Perform | Get Alert |
| 03/06/2024 | Buy Now | 22.59% | Argus Research | Kevin Heal | $225 → $245 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | 12.58% | Barclays | Benjamin Budish | $222 → $225 | Maintains | Equal-Weight | Get Alert |
| 01/08/2024 | Buy Now | 11.08% | Barclays | Benjamin Budish | $244 → $222 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 01/04/2024 | Buy Now | -9.93% | Rosenblatt | Andrew Bond | → $180 | Reiterates | Sell → Sell | Get Alert |
| 01/03/2024 | Buy Now | -2.43% | Goldman Sachs | Alexander Blostein | → $195 | Downgrade | Neutral → Sell | Get Alert |
| 10/26/2023 | Buy Now | 22.09% | Barclays | Benjamin Budish | $247 → $244 | Maintains | Overweight | Get Alert |
| 10/26/2023 | Buy Now | 10.08% | Morgan Stanley | Mike Cyprys | $215 → $220 | Maintains | Equal-Weight | Get Alert |
| 10/26/2023 | Buy Now | -9.93% | Rosenblatt | Andrew Bond | $173 → $180 | Maintains | Sell | Get Alert |
| 10/12/2023 | Buy Now | 20.09% | Citigroup | Christopher Allen | $215 → $240 | Maintains | Buy | Get Alert |
| 10/11/2023 | Buy Now | -1.43% | JP Morgan | Kenneth Billingsley | $190 → $197 | Maintains | Neutral | Get Alert |
| 10/11/2023 | Buy Now | 7.58% | Morgan Stanley | Mike Cyprys | $211 → $215 | Maintains | Equal-Weight | Get Alert |
| 10/11/2023 | Buy Now | 20.09% | Deutsche Bank | Brian Bedell | $224 → $240 | Maintains | Buy | Get Alert |
| 10/10/2023 | Buy Now | 23.59% | Barclays | Benjamin Budish | $230 → $247 | Maintains | Overweight | Get Alert |
| 10/04/2023 | Buy Now | -13.44% | Rosenblatt | Andrew Bond | → $173 | Reiterates | Sell → Sell | Get Alert |
| 09/06/2023 | Buy Now | 2.08% | B of A Securities | Craig Siegenthaler | $167 → $204 | Upgrade | Underperform → Neutral | Get Alert |
| 07/27/2023 | Buy Now | 15.09% | Barclays | Benjamin Budish | $215 → $230 | Maintains | Overweight | Get Alert |
| 07/27/2023 | Buy Now | 0.08% | Keefe, Bruyette & Woods | Kyle Voigt | $197 → $200 | Maintains | Market Perform | Get Alert |
| 07/27/2023 | Buy Now | 11.08% | Oppenheimer | Owen Lau | → $222 | Reiterates | Outperform → Outperform | Get Alert |
| 07/27/2023 | Buy Now | 5.58% | Morgan Stanley | Mike Cyprys | $210 → $211 | Maintains | Equal-Weight | Get Alert |
| 07/27/2023 | Buy Now | 7.58% | Citigroup | Christopher Allen | $210 → $215 | Maintains | Buy | Get Alert |
| 07/27/2023 | Buy Now | -13.44% | Rosenblatt | Andrew Bond | $169 → $173 | Maintains | Sell | Get Alert |
| 07/13/2023 | Buy Now | 5.08% | Morgan Stanley | Mike Cyprys | $208 → $210 | Maintains | Equal-Weight | Get Alert |
| 07/06/2023 | Buy Now | 5.08% | Citigroup | Christopher Allen | → $210 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | Buy Now | -15.44% | Rosenblatt | Andrew Bond | $161 → $169 | Maintains | Sell | Get Alert |
| 06/28/2023 | Buy Now | 7.58% | Barclays | Benjamin Budish | → $215 | Initiates | → Overweight | Get Alert |
| 04/19/2023 | Buy Now | -2.93% | JP Morgan | Kenneth Billingsley | $196 → $194 | Maintains | Neutral | Get Alert |
| 04/12/2023 | Buy Now | 10.58% | Oppenheimer | Owen Lau | $213 → $221 | Maintains | Outperform | Get Alert |
| 04/11/2023 | Buy Now | 4.08% | Morgan Stanley | Mike Cyprys | $201 → $208 | Maintains | Equal-Weight | Get Alert |
| 04/05/2023 | Buy Now | -19.44% | Rosenblatt | Andrew Bond | → $161 | Reiterates | → Sell | Get Alert |
| 02/13/2023 | Buy Now | 0.58% | Morgan Stanley | Michael Cyprys | $196 → $201 | Maintains | Equal-Weight | Get Alert |
| 02/09/2023 | Buy Now | -19.44% | Rosenblatt | Andrew Bond | → $161 | Reiterates | → Sell | Get Alert |
| 02/09/2023 | Buy Now | 3.58% | Credit Suisse | Gautam Sawant | $198 → $207 | Maintains | Outperform | Get Alert |
| 02/07/2023 | Buy Now | -0.93% | Credit Suisse | Gautam Sawant | $192 → $198 | Maintains | Outperform | Get Alert |
| 01/19/2023 | Buy Now | 6.58% | Oppenheimer | Colin Rusch | $218 → $213 | Maintains | Outperform | Get Alert |
| 01/11/2023 | Buy Now | -1.93% | Morgan Stanley | Michael Cyprys | $208 → $196 | Maintains | Equal-Weight | Get Alert |
| 01/05/2023 | Buy Now | -4.43% | Credit Suisse | Gautam Sawant | → $191 | Upgrade | Neutral → Outperform | Get Alert |
| 12/19/2022 | Buy Now | 25.09% | Piper Sandler | Richard Repetto | — | Maintains | Overweight | Get Alert |
| 10/27/2022 | Buy Now | 4.08% | Morgan Stanley | Michael Cyprys | $213 → $208 | Maintains | Equal-Weight | Get Alert |
| 10/12/2022 | Buy Now | 6.58% | Morgan Stanley | Michael Cyprys | $226 → $213 | Maintains | Equal-Weight | Get Alert |
| 10/12/2022 | Buy Now | — | Deutsche Bank | Brian Bedell | — | Upgrade | Hold → Buy | Get Alert |
| 10/12/2022 | Buy Now | 10.08% | Citigroup | Christopher Allen | → $220 | Initiates | → Buy | Get Alert |
| 10/05/2022 | Buy Now | -19.44% | Rosenblatt | Andrew Bond | $171 → $161 | Maintains | Sell | Get Alert |
| 09/06/2022 | Buy Now | 5.08% | Credit Suisse | Gautam Sawant | $216 → $210 | Maintains | Neutral | Get Alert |
| 08/17/2022 | Buy Now | -14.44% | Rosenblatt | Andrew Bond | → $171 | Initiates | → Sell | Get Alert |
| 08/15/2022 | Buy Now | — | Raymond James | Patrick O'Shaughnessy | — | Downgrade | Outperform → Market Perform | Get Alert |
| 08/12/2022 | Buy Now | 6.08% | Deutsche Bank | Brian Bedell | $208 → $212 | Maintains | Hold | Get Alert |
| 08/03/2022 | Buy Now | 8.08% | Credit Suisse | Gautam Sawant | $218 → $216 | Maintains | Neutral | Get Alert |
| 08/02/2022 | Buy Now | 20.09% | UBS | Alex Kramm | $246 → $240 | Maintains | Buy | Get Alert |
| 07/28/2022 | Buy Now | 13.08% | Morgan Stanley | Michael Cyprys | $242 → $226 | Maintains | Equal-Weight | Get Alert |
| 07/28/2022 | Buy Now | 9.08% | Credit Suisse | Gautam Sawant | $233 → $218 | Maintains | Neutral | Get Alert |
| 07/19/2022 | Buy Now | 21.09% | Morgan Stanley | Michael Cyprys | $280 → $242 | Maintains | Equal-Weight | Get Alert |
| 07/13/2022 | Buy Now | 6.58% | Deutsche Bank | Brian Bedell | $210 → $213 | Maintains | Hold | Get Alert |
| 07/06/2022 | Buy Now | 16.59% | Credit Suisse | Gautam Sawant | $242 → $233 | Maintains | Neutral | Get Alert |
| 07/06/2022 | Buy Now | 23.09% | UBS | Alex Kramm | $258 → $246 | Maintains | Buy | Get Alert |
| 07/06/2022 | Buy Now | 17.59% | Raymond James | Patrick O'Shaughnessy | $254 → $235 | Maintains | Outperform | Get Alert |
| 06/10/2022 | Buy Now | 17.59% | Atlantic Equities | Simon Clinch | → $235 | Upgrade | Neutral → Overweight | Get Alert |
| 06/03/2022 | Buy Now | 29.1% | UBS | Alex Kramm | $284 → $258 | Maintains | Buy | Get Alert |
| 05/25/2022 | Buy Now | 11.58% | Oppenheimer | Owen Lau | → $223 | Upgrade | Perform → Outperform | Get Alert |
| 05/19/2022 | Buy Now | 5.08% | Deutsche Bank | Brian Bedell | $262 → $210 | Maintains | Hold | Get Alert |
| 05/16/2022 | Buy Now | 15.09% | Argus Research | Stephen Biggar | → $230 | Upgrade | Hold → Buy | Get Alert |
| 04/28/2022 | Buy Now | 40.11% | Citigroup | Ben Herbert | $275 → $280 | Maintains | Buy | Get Alert |
| 04/28/2022 | Buy Now | 29.6% | Credit Suisse | Gautam Sawant | $255 → $259 | Maintains | Neutral | Get Alert |
| 04/28/2022 | Buy Now | 36.6% | Rosenblatt | Sean Horgan | $267 → $273 | Maintains | Neutral | Get Alert |
| 04/28/2022 | Buy Now | 27.1% | Raymond James | Patrick O'Shaughnessy | $265 → $254 | Maintains | Outperform | Get Alert |
| 04/14/2022 | Buy Now | 33.6% | Rosenblatt | Sean Horgan | $268 → $267 | Maintains | Neutral | Get Alert |
| 04/13/2022 | Buy Now | 35.6% | Morgan Stanley | Michael Cyprys | $255 → $271 | Maintains | Equal-Weight | Get Alert |
| 04/05/2022 | Buy Now | 31.1% | Credit Suisse | Gautam Sawant | $265 → $262 | Maintains | Neutral | Get Alert |
| 03/08/2022 | Buy Now | 34.1% | Rosenblatt | Sean Horgan | $260 → $268 | Maintains | Neutral | Get Alert |
| 03/03/2022 | Buy Now | 37.6% | UBS | Alex Kramm | $267 → $275 | Maintains | Buy | Get Alert |
| 03/03/2022 | Buy Now | 32.6% | Credit Suisse | Gautam Sawant | $258 → $265 | Maintains | Neutral | Get Alert |
| 02/15/2022 | Buy Now | 29.1% | Credit Suisse | Gautam Sawant | → $258 | Initiates | → Neutral | Get Alert |
| 02/11/2022 | Buy Now | 27.6% | Morgan Stanley | Michael Cyprys | $234 → $255 | Maintains | Equal-Weight | Get Alert |
| 02/10/2022 | Buy Now | 32.6% | Raymond James | Patrick O'Shaughnessy | $240 → $265 | Maintains | Outperform | Get Alert |
| 02/08/2022 | Buy Now | — | Atlantic Equities | Simon Clinch | — | Downgrade | Overweight → Neutral | Get Alert |
| 01/20/2022 | Buy Now | 27.1% | Rosenblatt | Sean Horgan | → $254 | Upgrade | Sell → Neutral | Get Alert |
| 01/05/2022 | Buy Now | 20.09% | Raymond James | Patrick O'Shaughnessy | $230 → $240 | Maintains | Outperform | Get Alert |
| 10/28/2021 | Buy Now | 17.09% | Morgan Stanley | Michael Cyprys | — | Maintains | Equal-Weight | Get Alert |
| 10/28/2021 | Buy Now | -1.43% | Rosenblatt | Sean Horgan | — | Maintains | Sell | Get Alert |
| 10/28/2021 | Buy Now | 15.09% | Raymond James | Patrick O'Shaughnessy | — | Maintains | Outperform | Get Alert |
| 10/08/2021 | Buy Now | 8.58% | Morgan Stanley | Michael Cyprys | — | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for CME Gr (CME) stock?
The latest price target for CME Gr (NASDAQ:CME) was reported by Barclays on July 10, 2024. The analyst firm set a price target for $208.00 expecting CME to rise to within 12 months (a possible 4.08% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CME Gr (CME)?
The latest analyst rating for CME Gr (NASDAQ:CME) was provided by Barclays, and CME Gr maintained their equal-weight rating.
When was the last upgrade for CME Gr (CME)?
The last upgrade for CME Group Inc happened on September 6, 2023 when B of A Securities raised their price target to $204. B of A Securities previously had an underperform for CME Group Inc.
When was the last downgrade for CME Gr (CME)?
The last downgrade for CME Group Inc happened on June 21, 2024 when JP Morgan changed their price target from $206 to $187 for CME Group Inc.
When is the next analyst rating going to be posted or updated for CME Gr (CME)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CME Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CME Gr was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating CME Gr (CME) correct?
While ratings are subjective and will change, the latest CME Gr (CME) rating was a maintained with a price target of $228.00 to $208.00. The current price CME Gr (CME) is trading at is $199.85, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.